MCID: CNN003
MIFTS: 70

Conn's Syndrome

Categories: Blood diseases, Cancer diseases, Endocrine diseases, Metabolic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Conn's Syndrome

MalaCards integrated aliases for Conn's Syndrome:

Name: Conn's Syndrome 12 77 15
Cushing's Syndrome 12 77 54 55 30 6 44
Hyperaldosteronism 12 77 56 45 41 17 74
Cushing Syndrome 12 54 38 56 45 17 74
Primary Aldosteronism 12 77 54 38 15
Primary Hyperaldosteronism 12 54 6 15
Hypercortisolism 54 55 30 56
Conn Syndrome 12 54 74
Acth Syndrome, Ectopic 17 74
Adrenal Hyperfunction Resulting from Pituitary Acth Excess 54
Ectopic Adrenocorticotropic Hormone Syndrome 54
Nodular Primary Adrenocortical Dysplasia 54
Adrenal Gland Hyperfunction 74
Adrenal Cushing's Syndrome 74
Adrenal Cortical Adenoma 74
Mineralocorticoid Excess 54
Adrenal Cortex Adenoma 54
Ectopic Acth Syndrome 54
Aldosteronism Primary 56
Acth Syndrome Ectopic 56
Hyperadrenocorticism 54
Cushing's Disease 15

Classifications:



Summaries for Conn's Syndrome

NINDS : 55 Cushing's syndrome, also called hypercortisolism, is a rare endocrine disorder caused by chronic exposure of the body's tissues to excess levels of cortisol - a hormone naturally produced by the adrenal gland. Exposure to too much cortisol can occur from long-term use of synthetic glucocorticoid hormones to treat inflammatory illnesses. Pituitary adenomas (benign tumors of the pituitary gland) that secrete increased amounts of ACTH (adrenocorticotropic hormone, a substance that controls the release of cortisol) can also spur overproduction of cortisol. Tumors of the adrenal gland and ectopic ACTH syndrome (a condition in which ACTH is produced by various types of potentially malignant tumors that occur in different parts of the body) can cause similar problems with cortisol balance. Common symptoms of Cushing's syndrome include upper body obesity, severe fatigue and muscle weakness, high blood pressure, backache, elevated blood sugar, easy bruising, and bluish-red stretch marks on the skin. In women, there may be increased growth of facial and body hair, and menstrual periods may become irregular or stop completely. Neurological symptoms include difficulties with memory and neuromuscular disorders.

MalaCards based summary : Conn's Syndrome, also known as cushing's syndrome, is related to primary pigmented nodular adrenocortical disease and acth-secreting pituitary adenoma, and has symptoms including agitation and cushingoid facies. An important gene associated with Conn's Syndrome is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are Calcium signaling pathway and Renin secretion. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, testes and adrenal gland, and related phenotypes are thin skin and growth delay

Disease Ontology : 12 An adrenal gland hyperfunction disease that results in the overproduction of aldosterone by the adrenal glands.

NIH Rare Diseases : 54 Cushing's syndrome is an endocrine disorder caused by prolonged exposure of the body's tissues to high levels of cortisol (a hormone produced by the adrenal gland). It most commonly affects adults between age 20 and 50 years. Signs and symptoms of Cushing's syndrome include upper body obesity, fatigue, muscle weakness, high blood pressure, backache, high blood sugar, easy bruising and bluish-red stretch marks on the skin. Affected women may also experience irregular menstrual periods and increased growth of body and facial hair. This condition may be caused by a variety of factors including long-term use of corticosteroid medications, tumors in the pituitary gland or adrenal adenomas.Treatment depends on the underlying cause, but may include decreasing the dosage of corticosteroids or surgery to remove tumors.

MedlinePlus : 44 Cushing's syndrome is a hormonal disorder. The cause is long-term exposure to too much cortisol, a hormone that your adrenal gland makes. Sometimes, taking synthetic hormone medicine to treat an inflammatory disease leads to Cushing's. Some kinds of tumors produce a hormone that can cause your body to make too much cortisol. Cushing's syndrome is rare. Some symptoms are Upper body obesity Thin arms and legs Severe fatigue and muscle weakness High blood pressure High blood sugar Easy bruising Lab tests can show if you have it and find the cause. Your treatment will depend on why you have too much cortisol. If it is because you have been taking synthetic hormones, a lower dose may control your symptoms. If the cause is a tumor, surgery and other therapies may be needed. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Wikipedia : 77 Primary aldosteronism, also known as primary hyperaldosteronism or Conn''s syndrome, refers to the... more...

Related Diseases for Conn's Syndrome

Diseases related to Conn's Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 602)
# Related Disease Score Top Affiliating Genes
1 primary pigmented nodular adrenocortical disease 33.1 GNAS POMC PRKAR1A
2 acth-secreting pituitary adenoma 32.8 CRH NR3C1 POMC PRL
3 mccune-albright syndrome 32.4 GH1 GNAS PRL SST
4 familial hyperaldosteronism 32.4 AGTR1 CACNA1H CYP11B1 CYP11B2 KCNJ5
5 ectopic cushing syndrome 32.2 CRH POMC SST
6 pituitary tumors 32.1 GH1 GNAS POMC PRL SST
7 nelson syndrome 31.2 CRH NR3C1 POMC PRL SST
8 bronchial adenomas/carcinoids childhood 30.7 POMC SST
9 adrenal gland disease 30.7 CRH CYP11B1 CYP11B2 HSD11B2 KCNJ5 NR3C1
10 renovascular hypertension 30.5 AGTR1 NPPA REN
11 bronchus adenoma 30.5 POMC SST
12 aldosterone-producing adenoma 30.5 CYP11B2 CYP21A2 KCNJ5
13 hypokalemia 30.4 HSD11B2 NR3C1 NR3C2 POMC REN
14 malignant hypertension 30.4 AGTR1 NPPA REN
15 pituitary-dependent cushing's disease 30.3 CRH CYP21A2 POMC PRL SST
16 chromophobe adenoma 30.3 GH1 POMC PRL
17 mental depression 30.3 CRH NR3C1 POMC
18 arthrogryposis, distal, type 3 30.3 NR3C2 REN
19 polycystic ovary syndrome 30.2 CYP17A1 CYP21A2 PRL
20 gangliocytoma 30.2 CRH POMC
21 renal artery disease 30.2 AGTR1 REN
22 multiple endocrine neoplasia, type i 30.2 GNAS PRKAR1A PRL SST
23 lymphocytic hypophysitis 30.2 GH1 POMC
24 lipoid congenital adrenal hyperplasia 30.2 CYP11B1 CYP11B2 CYP17A1 CYP21A2 POMC REN
25 corticosteroid-binding globulin deficiency 30.1 HSD11B2 NR3C1 POMC
26 hypoadrenocorticism, familial 30.1 CRH CYP21A2 POMC
27 hypoadrenalism 30.1 CRH GH1 POMC
28 pituitary hormone deficiency, combined, 2 30.1 GH1 POMC PRL
29 pheochromocytoma 30.1 CRH POMC REN SST
30 hypoaldosteronism 30.1 CYP11B2 NPPA POMC REN
31 acute adrenal insufficiency 30.1 CYP21A2 POMC REN
32 adrenal cortical adenoma 30.0 CYP11B1 CYP17A1 CYP21A2 GIPR POMC PRKAR1A
33 glucose metabolism disease 30.0 POMC REN SST
34 apparent mineralocorticoid excess 30.0 HSD11B2 NR3C1 NR3C2 REN
35 fibrous dysplasia 30.0 GH1 GNAS PRL SST
36 hypothyroidism 29.9 GH1 GNAS POMC PRL
37 empty sella syndrome 29.9 GH1 POMC PRL
38 hypopituitarism 29.9 CRH GH1 POMC PRL
39 hyperinsulinism 29.9 GH1 KCNJ5 SST
40 sheehan syndrome 29.9 CRH POMC PRL
41 adrenal cortical hypofunction 29.9 CRH CYP21A2 POMC REN
42 diabetes insipidus 29.9 CRH POMC PRL REN
43 non-functioning pituitary adenoma 29.9 GH1 SST
44 pituitary apoplexy 29.9 POMC PRL
45 pituitary carcinoma 29.9 CRH POMC PRL SST
46 amenorrhea 29.8 CRH POMC PRL
47 precocious puberty 29.8 CYP21A2 GH1 GNAS
48 adenoma 29.8 CYP11B2 CYP21A2 GH1 GNAS HSD11B2 KCNJ5
49 acromegaly 29.8 GH1 GNAS POMC PRL SST
50 liddle syndrome 1 29.8 CYP11B2 HSD11B2 NR3C1 NR3C2 REN

Comorbidity relations with Conn's Syndrome via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Anxiety
Bronchitis Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Postinflammatory Pulmonary Fibrosis
Premature Ovarian Failure 7 Respiratory Failure
Rheumatoid Arthritis Status Asthmaticus
Temporal Arteritis

Graphical network of the top 20 diseases related to Conn's Syndrome:



Diseases related to Conn's Syndrome

Symptoms & Phenotypes for Conn's Syndrome

Human phenotypes related to Conn's Syndrome:

33 (show all 39)
# Description HPO Frequency HPO Source Accession
1 thin skin 33 hallmark (90%) HP:0000963
2 growth delay 33 hallmark (90%) HP:0001510
3 round face 33 hallmark (90%) HP:0000311
4 erectile abnormalities 33 hallmark (90%) HP:0100639
5 truncal obesity 33 hallmark (90%) HP:0001956
6 abnormal subcutaneous fat tissue distribution 33 hallmark (90%) HP:0007552
7 depressivity 33 frequent (33%) HP:0000716
8 diabetes mellitus 33 frequent (33%) HP:0000819
9 hypertension 33 frequent (33%) HP:0000822
10 muscle weakness 33 frequent (33%) HP:0001324
11 hypokalemia 33 frequent (33%) HP:0002900
12 fatigue 33 frequent (33%) HP:0012378
13 osteoporosis 33 frequent (33%) HP:0000939
14 irritability 33 frequent (33%) HP:0000737
15 generalized hirsutism 33 frequent (33%) HP:0002230
16 acne 33 frequent (33%) HP:0001061
17 anxiety 33 frequent (33%) HP:0000739
18 striae distensae 33 frequent (33%) HP:0001065
19 decreased fertility 33 frequent (33%) HP:0000144
20 purpura 33 frequent (33%) HP:0000979
21 nephrolithiasis 33 frequent (33%) HP:0000787
22 recurrent fractures 33 frequent (33%) HP:0002757
23 bruising susceptibility 33 frequent (33%) HP:0000978
24 sleep disturbance 33 occasional (7.5%) HP:0002360
25 cataract 33 occasional (7.5%) HP:0000518
26 reduced consciousness/confusion 33 occasional (7.5%) HP:0004372
27 myopathy 33 occasional (7.5%) HP:0003198
28 abdominal pain 33 occasional (7.5%) HP:0002027
29 secondary amenorrhea 33 occasional (7.5%) HP:0000869
30 dilated cardiomyopathy 33 occasional (7.5%) HP:0001644
31 psychosis 33 occasional (7.5%) HP:0000709
32 telangiectasia of the skin 33 occasional (7.5%) HP:0100585
33 hyponatremia 33 occasional (7.5%) HP:0002902
34 hypercholesterolemia 33 occasional (7.5%) HP:0003124
35 hypercalcemia 33 occasional (7.5%) HP:0003072
36 abnormality of the gastric mucosa 33 occasional (7.5%) HP:0004295
37 increased circulating cortisol level 33 occasional (7.5%) HP:0003118
38 neoplasm of the adrenal gland 33 occasional (7.5%) HP:0100631
39 avascular necrosis 33 occasional (7.5%) HP:0010885

UMLS symptoms related to Conn's Syndrome:


agitation, cushingoid facies

GenomeRNAi Phenotypes related to Conn's Syndrome according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.32 AGTR1 CYP11B1 CYP21A2 GIPR GNAS HSD11B2

MGI Mouse Phenotypes related to Conn's Syndrome:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 AGTR1 CACNA1H CRH CYP11B1 CYP17A1 GNAS
2 cardiovascular system MP:0005385 10.29 AGTR1 CACNA1H CYP11B1 CYP11B2 GNAS HSD11B2
3 homeostasis/metabolism MP:0005376 10.27 AGTR1 CRH CYP11B1 CYP11B2 CYP17A1 GIPR
4 growth/size/body region MP:0005378 10.25 AGTR1 CACNA1H CRH CYP11B1 CYP11B2 CYP17A1
5 adipose tissue MP:0005375 10.11 AGTR1 CRH CYP11B2 CYP17A1 GNAS NR3C1
6 endocrine/exocrine gland MP:0005379 10.11 CRH CYP11B1 CYP11B2 GIPR GNAS NR3C1
7 hematopoietic system MP:0005397 10.1 AGTR1 CRH CYP11B2 GNAS NPPA NR3C1
8 immune system MP:0005387 10.02 AGTR1 CRH CYP11B2 GNAS NR3C1 POMC
9 muscle MP:0005369 9.81 CACNA1H CYP11B1 GNAS HSD11B2 NPPA NR3C1
10 liver/biliary system MP:0005370 9.8 CRH CYP11B2 GNAS NR3C1 POMC PRKAR1A
11 nervous system MP:0003631 9.7 AGTR1 CACNA1H CRH CYP11B2 GNAS NR3C1
12 renal/urinary system MP:0005367 9.36 AGTR1 CRH CYP11B1 CYP11B2 GNAS HSD11B2

Drugs & Therapeutics for Conn's Syndrome

Drugs for Conn's Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
3
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
4
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
5
Captopril Approved Phase 4 62571-86-2 44093
6
Eplerenone Approved Phase 4,Phase 3,Not Applicable 107724-20-9 443872 150310
7
Losartan Approved Phase 4 114798-26-4 3961
8
Angiotensin II Approved, Investigational Phase 4,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
9
Mifepristone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 84371-65-3 55245
10 Vasoconstrictor Agents Phase 4,Phase 3,Not Applicable
11 Anti-Asthmatic Agents Phase 4,Phase 3,Not Applicable
12 Neurotransmitter Agents Phase 4,Phase 3,Not Applicable
13 Adrenergic beta-Agonists Phase 4,Phase 3,Not Applicable
14 Epinephryl borate Phase 4,Phase 3,Phase 2,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Adrenergic alpha-Agonists Phase 4,Phase 3,Not Applicable
18 Mydriatics Phase 4,Phase 3,Not Applicable
19 Sympathomimetics Phase 4,Phase 3,Not Applicable
20 Adrenergic Agonists Phase 4,Phase 3,Not Applicable
21 Bronchodilator Agents Phase 4,Phase 3,Not Applicable
22 Adrenergic Agents Phase 4,Phase 3,Not Applicable
23 Respiratory System Agents Phase 4,Phase 3,Not Applicable
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Dopamine Agents Phase 4
28 Dopamine agonists Phase 4
29 Antiparkinson Agents Phase 4
30 HIV Protease Inhibitors Phase 4
31 Angiotensin-Converting Enzyme Inhibitors Phase 4,Not Applicable
32
protease inhibitors Phase 4
33 Antihypertensive Agents Phase 4,Phase 3,Not Applicable
34 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Insulin, Globin Zinc Phase 4,Phase 2,Not Applicable
36 Mineralocorticoids Phase 4,Phase 3,Not Applicable
37 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3,Not Applicable
38 Natriuretic Agents Phase 4,Phase 3,Not Applicable
39 insulin Phase 4,Phase 2,Not Applicable
40 Diuretics, Potassium Sparing Phase 4,Phase 3,Not Applicable
41 diuretics Phase 4,Phase 3,Not Applicable
42 Kallikreins Phase 4
43 Angiotensin Receptor Antagonists Phase 4
44 Coagulants Phase 4
45 Anti-Arrhythmia Agents Phase 4
46 Angiotensinogen Phase 4,Not Applicable
47 Giapreza Phase 4,Not Applicable
48 Angiotensin II Type 1 Receptor Blockers Phase 4
49 Fertility Agents Phase 4
50 Luteolytic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
2 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
3 Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism Completed NCT00155064 Phase 4 captopril, Losartan (drug)
4 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
5 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4 Mifepristone
6 Aldosterone Antagonism and Microvascular Function Terminated NCT01887119 Phase 4 Eplerenone
7 SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. Completed NCT01096654 Phase 3
8 Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension Completed NCT00138944 Phase 3 placebo;eplerenone
9 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
10 Treatment for Endogenous Cushing's Syndrome Completed NCT01838551 Phase 3 COR-003
11 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
12 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
13 Prevention of Metabolic Complications of Glucocorticoid Excess Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
14 Effects of IL-1 Beta on the HPA-axis in Obese Persons Completed NCT02227420 Phase 3 Anakinra
15 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
16 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
17 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
18 Adrenal Artery Ablation for Primary Aldosteronism Recruiting NCT03653845 Phase 3 Sequenced antihypertensvie drugs with titrated dosage
19 Adrenal Artery Ablation Treats Primary Aldosteronism Recruiting NCT03398785 Phase 3
20 Adrenal Artery Ablation for Uncontrolled Hypertension Recruiting NCT03660397 Phase 3 Traditional triple antihypertensive treatment
21 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Recruiting NCT03697109 Phase 3 Relacorilant
22 Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome Recruiting NCT02297945 Phase 3 metyrapone
23 A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. Recruiting NCT03277690 Phase 3 Levoketoconazole;Placebo
24 Open-label Treatment in Cushing's Syndrome Recruiting NCT03621280 Phase 3 Levoketoconazole
25 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
26 Open-label Study on Treatment of Primary Aldosteronism With Everolimus Completed NCT03174171 Phase 2 Everolimus 0.75 mg
27 Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism Completed NCT00732771 Phase 2 LCI699
28 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
29 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Completed NCT00001849 Phase 1, Phase 2 Pentetreotide;18F-DOPA
30 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
31 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
32 Glucocorticoid Receptor Antagonism in Subclinical Cushings Completed NCT00721201 Phase 1, Phase 2 Mifepristone
33 Mifepristone for Metabolic Syndrome Completed NCT01419535 Phase 1, Phase 2 Mifepristone;Placebo
34 A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome Recruiting NCT03053271 Phase 2 ATR-101;Placebo
35 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
36 Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs Recruiting NCT02611258 Phase 2 Tadalafil
37 Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome Recruiting NCT02019706 Phase 2 F-DOPA PET Scan;Mifepristone;Ga-DOTATATE;Octreoscan
38 Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 Recruiting NCT03606408 Phase 2 osilodrostat
39 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
40 Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus Recruiting NCT03052400 Phase 2 Mifepristone 600 mg daily;Placebo
41 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
42 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone
43 Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
44 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
45 Treatment of Cushing's Disease With R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
46 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
47 Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism Not yet recruiting NCT03821571 Phase 1
48 Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study Unknown status NCT02257450
49 Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation Unknown status NCT01267747
50 Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism Unknown status NCT00173082

Search NIH Clinical Center for Conn's Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: cushing syndrome

Genetic Tests for Conn's Syndrome

Genetic tests related to Conn's Syndrome:

# Genetic test Affiliating Genes
1 Cushing's Syndrome 30 GNAS
2 Hypercortisolism 30

Anatomical Context for Conn's Syndrome

MalaCards organs/tissues related to Conn's Syndrome:

42
Pituitary, Testes, Adrenal Gland, Thyroid, Kidney, Skin, Bone

Publications for Conn's Syndrome

Articles related to Conn's Syndrome:

(show top 50) (show all 3222)
# Title Authors Year
1
Cushing's Syndrome: A Large Adenoma of Adrenal Gland. ( 31073111 )
2019
2
Exacerbation of Cushing's syndrome during pregnancy: stimulation of a cortisol-secreting adrenocortical adenoma by ACTH originating from the foeto-placental unit. ( 30738017 )
2019
3
Robot-assisted Partial Adrenalectomy for the Treatment of Conn's Syndrome: Surgical Technique, and Perioperative and Functional Outcomes. ( 30077398 )
2019
4
Increased myocardial sodium signal intensity in Conn's syndrome detected by 23Na magnetic resonance imaging. ( 30307545 )
2019
5
23-Sodium magnetic resonance imaging of the human heart revisited: new insights in patients with Conn's syndrome. ( 30329027 )
2019
6
Perioperative management of patient with Conn's syndrome and severe hypokalaemia: How low is too low? ( 30745619 )
2019
7
Intractable Hypokalemia: a Red Herring for Rapidly Evolving Ectopic Cushing's Syndrome. ( 30685911 )
2019
8
Arterial thrombosis as primary presentation of endogenous Cushing's syndrome. ( 30733248 )
2019
9
Performance of LC-MS/MS and immunoassay based 24-h urine free cortisol in the diagnosis of Cushing's syndrome. ( 30959155 )
2019
10
Unmasking of Sarcoidosis After Successful Management of Cushing's Syndrome. ( 30911452 )
2019
11
Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission. ( 30467627 )
2019
12
Peripheral primitive neuroectodermal tumor associated with paraneoplastic Cushing's syndrome: The rare case. ( 30581565 )
2019
13
A case of subclinical Cushing's syndrome presenting as catatonia. ( 30618203 )
2019
14
Local hyperthermia cleared multifarious viral warts in a patient with Cushing's syndrome. ( 30633835 )
2019
15
Minimally invasive approach to the adrenal gland in obese patients with Cushing's syndrome. ( 30663461 )
2019
16
A case of autonomous cortisol secretion in a patient with subclinical Cushing's syndrome, GNAS mutation, and paradoxical cortisol response to dexamethasone. ( 30670014 )
2019
17
Changes in glucose metabolism based on 75-g oral glucose tolerance tests before and after surgery for adrenal Cushing's syndrome. ( 30674738 )
2019
18
Medical Management of Cushing's Syndrome: Current and Emerging Treatments. ( 31098899 )
2019
19
The incidence of endogenous Cushing's syndrome in the modern era. ( 31094003 )
2019
20
Heterophile Antibody to Adrenocorticotropin Hormone Interfering with the Investigation of Cushing's Syndrome. ( 31093000 )
2019
21
Cushing's syndrome-an epidemiological study based on a canine population of 21,281 dogs. ( 31086762 )
2019
22
Pattern of Lipid Abnormalities Among South Asian Indians With Cushing's Syndrome and the Short Term Impact of Surgical Correction of Hypercortisolism. ( 31071735 )
2019
23
Cabergoline in Severe Ectopic or Occult Cushing's Syndrome. ( 31048558 )
2019
24
Ectopic cushing's syndrome due to corticotropin releasing hormone. ( 31041631 )
2019
25
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse. ( 31023618 )
2019
26
Plasma steroid profiles in subclinical compared to overt adrenal Cushing's syndrome. ( 30977834 )
2019
27
Cushing’s Syndrome and Cardiovascular Risk ( 30939868 )
2019
28
Elevated resting-state connectivity in the medial temporal lobe and the prefrontal cortex among patients with Cushing's syndrome in remission. ( 30939453 )
2019
29
Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing's Syndrome Rat Model. ( 30915117 )
2019
30
Demographic Characteristics, Etiology, and Comorbidities of Patients with Cushing's Syndrome: A 10-Year Retrospective Study at a Large General Hospital in China. ( 30915114 )
2019
31
Factitious Cushing's Syndrome: A Diagnosis to Consider When Evaluating Hypercortisolism. ( 30886602 )
2019
32
Hair glucocorticoids as biomarker for endogenous Cushing's syndrome: validation in two independent cohorts. ( 30759443 )
2019
33
Correction to: Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission. ( 30680542 )
2019
34
Alterations in hypothalamic-pituitary-adrenal function immediately after resection of adrenal adenomas in patients with Cushing's syndrome and others with incidentalomas and subclinical hypercortisolism. ( 30259310 )
2019
35
Outcomes of Adrenal Venous Sampling in Patients with Bilateral Adrenal Masses and ACTH-Independent Cushing's Syndrome. ( 30232569 )
2019
36
Bilateral Adrenocortical Adenomas along with Virilization and Cushing's Syndrome. ( 30210105 )
2019
37
Advances in the medical treatment of Cushing's syndrome. ( 30033041 )
2019
38
Diagnostic value of the late-night salivary cortisol in the diagnosis of clinical and subclinical Cushing's syndrome: results of a single-center 7-year experience. ( 30030305 )
2019
39
Bilateral vertebral artery dissection revealing Cushing's syndrome. ( 29555079 )
2019
40
Comparison of adipose tissue derived genes in endogenous Cushing's syndrome versus diet-induced obesity. ( 30480750 )
2019
41
A unique case of ectopic Cushing's syndrome from a thymic neuroendocrine carcinoma. ( 30802210 )
2019
42
Intestinal Perforation in ACTH-Dependent Cushing's Syndrome. ( 31001560 )
2019
43
An ectopic adrenocortical adenoma in renal hilum presenting with Cushing's syndrome: A case report and literature review. ( 30557981 )
2018
44
PREOPERATIVE TREATMENT WITH METYRAPONE IN PATIENTS WITH CUSHING'S SYNDROME DUE TO ADRENAL ADENOMA. ( 30352400 )
2018
45
Hypokalemia associated with pseudo-Cushing's syndrome and magnesium deficiency induced by chronic alcohol abuse. ( 29450857 )
2018
46
Laparoscopic Adrenalectomy for Conn's Syndrome is Beneficial to Patients and is Cost Effective in England. ( 28498785 )
2018
47
Glucocorticoid-remediable aldosteronism in a young adult with a family history of Conn's syndrome. ( 29445488 )
2018
48
Short- and long-term results of laparoscopic adrenalectomy for Conn's syndrome. ( 30302141 )
2018
49
Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. ( 29515517 )
2018
50
Histone deacetylase inhibition ameliorates hypertension and hyperglycemia in a model of Cushing's syndrome. ( 28928236 )
2018

Variations for Conn's Syndrome

ClinVar genetic disease variations for Conn's Syndrome:

6 (show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 GNAS NM_000516.5(GNAS): c.1A> G (p.Met1Val) single nucleotide variant Pathogenic/Likely pathogenic rs137854530 GRCh37 Chromosome 20, 57466782: 57466782
2 GNAS NM_000516.5(GNAS): c.1A> G (p.Met1Val) single nucleotide variant Pathogenic/Likely pathogenic rs137854530 GRCh38 Chromosome 20, 58891727: 58891727
3 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
4 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh38 Chromosome 20, 58909365: 58909365
5 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
6 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh38 Chromosome 20, 58909366: 58909366
7 GNAS NM_000516.5(GNAS): c.601C> A (p.Arg201Ser) single nucleotide variant Pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
8 GNAS NM_000516.5(GNAS): c.601C> A (p.Arg201Ser) single nucleotide variant Pathogenic rs11554273 GRCh38 Chromosome 20, 58909365: 58909365
9 CACNA1H NM_021098.2(CACNA1H): c.4645A> G (p.Met1549Val) single nucleotide variant Pathogenic rs786205050 GRCh37 Chromosome 16, 1262024: 1262024
10 CACNA1H NM_021098.2(CACNA1H): c.4645A> G (p.Met1549Val) single nucleotide variant Pathogenic rs786205050 GRCh38 Chromosome 16, 1212024: 1212024
11 GNAS NM_001077488.3(GNAS): c.85C> T (p.Gln29Ter) single nucleotide variant Pathogenic rs1057518907 GRCh37 Chromosome 20, 57466866: 57466866
12 GNAS NM_001077488.3(GNAS): c.85C> T (p.Gln29Ter) single nucleotide variant Pathogenic rs1057518907 GRCh38 Chromosome 20, 58891811: 58891811
13 GNAS NM_080425.3(GNAS): c.1200C> A (p.Ala400=) single nucleotide variant Uncertain significance rs908810796 GRCh37 Chromosome 20, 57429520: 57429520
14 GNAS NM_080425.3(GNAS): c.1200C> A (p.Ala400=) single nucleotide variant Uncertain significance rs908810796 GRCh38 Chromosome 20, 58854465: 58854465
15 GNAS NM_080425.3(GNAS): c.1455C> A (p.Ala485=) single nucleotide variant Uncertain significance rs55890501 GRCh37 Chromosome 20, 57429775: 57429775
16 GNAS NM_080425.3(GNAS): c.1455C> A (p.Ala485=) single nucleotide variant Uncertain significance rs55890501 GRCh38 Chromosome 20, 58854720: 58854720

Cosmic variations for Conn's Syndrome:

9 (show top 50) (show all 82)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM11552 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.775G>T p.D259Y 17:7674188-7674188 0
2 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.587G>T p.R196L 17:7674944-7674944 0
3 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.736A>G p.M246V 17:7674227-7674227 0
4 COSM43678 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.305C>T p.T102I 17:7676064-7676064 0
5 COSM1367296 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.2094G>T p.R698S 13:48459821-48459821 0
6 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.1960G>A p.V654M 13:48456349-48456349 0
7 COSM326321 RB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.1994T>G p.L665R 13:48459721-48459721 0
8 COSM26707 PRKAR1A adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.664A>G p.K222E 17:68525868-68525868 0
9 COSM26708 PRKAR1A adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.892-1G>A p.? 17:68529919-68529919 0
10 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.617T>G p.L206R 19:14097604-14097604 0
11 COSM5885970 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.262C>G p.H88D 19:14102890-14102890 0
12 COSM6944239 PLCG2 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.615C>A p.F205L 16:81870902-81870902 0
13 COSM6944237 NUP93 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.2172G>T p.Q724H 16:56839556-56839556 0
14 COSM584 NRAS adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.182A>G p.Q61R 1:114713908-114713908 0
15 COSM6944241 NF1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.3265G>T p.E1089* 17:31232140-31232140 0
16 COSM22568 MEN1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.325G>T p.E109* 11:64809785-64809785 0
17 COSM23025 MEN1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.1654A>T p.T552S 11:64804513-64804513 0
18 COSM6944234 KMT2A adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.8408C>A p.S2803* 11:118504309-118504309 0
19 COSM1684717 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.451G>A p.G151R 11:128911724-128911724 0
20 COSM1684718 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.503T>G p.L168R 11:128911776-128911776 0
21 COSM1684720 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.451G>C p.G151R 11:128911724-128911724 0
22 COSM4745630 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.343C>T p.R115W 11:128911616-128911616 0
23 COSM1732665 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.376T>C p.W126R 11:128911649-128911649 0
24 COSM1717390 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.433G>C p.E145Q 11:128911706-128911706 0
25 COSM1684719 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.472A>G p.T158A 11:128911745-128911745 0
26 COSM4745631 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.737A>G p.E246G 11:128912010-128912010 0
27 COSM5546565 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.439G>C p.E147Q 11:128911712-128911712 0
28 COSM5990170 KCNJ5 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.461T>G p.F154C 11:128911734-128911734 0
29 COSM27887 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.601C>T p.R201C 20:58909365-58909365 0
30 COSM27899 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.601C>A p.R201S 20:58909365-58909365 0
31 COSM27895 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.602G>A p.R201H 20:58909366-58909366 0
32 COSM4962873 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.679C>G p.Q227E 20:58909540-58909540 0
33 COSM5667 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.134C>T p.S45F 3:41224646-41224646 0
34 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.133T>C p.S45P 3:41224645-41224645 0
35 COSM5692 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.134C>A p.S45Y 3:41224646-41224646 0
36 COSM5689 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.134C>G p.S45C 3:41224646-41224646 0
37 COSM17661 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.130C>G p.P44A 3:41224642-41224642 0
38 COSM5678 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.107A>C p.H36P 3:41224619-41224619 0
39 COSM5664 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.121A>G p.T41A 3:41224633-41224633 0
40 COSM5686 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.100G>A p.G34R 3:41224612-41224612 0
41 COSM5679 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.110C>G p.S37C 3:41224622-41224622 0
42 COSM1423013 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.137T>C p.L46P 3:41224649-41224649 0
43 COSM5988492 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.101G>C p.G34A 3:41224613-41224613 0
44 COSM5677 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.98C>G p.S33C 3:41224610-41224610 0
45 COSM5681 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.95A>G p.D32G 3:41224607-41224607 0
46 COSM5693 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.118A>G p.T40A 3:41224630-41224630 0
47 COSM6944226 CDC73 adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.790G>T p.A264S 1:193147927-193147927 0
48 COSM1717762 CACNA1D adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.776T>A p.V259D 3:53665669-53665669 0
49 COSM1738073 CACNA1D adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.1207G>C p.G403R 3:53673803-53673803 0
50 COSM1738072 CACNA1D adrenal gland,adrenal gland,adrenal cortical adenoma,NS c.2301C>G p.F767L 3:53730461-53730461 0

Expression for Conn's Syndrome

Search GEO for disease gene expression data for Conn's Syndrome.

Pathways for Conn's Syndrome

Pathways related to Conn's Syndrome according to KEGG:

38
# Name Kegg Source Accession
1 Calcium signaling pathway hsa04020
2 Renin secretion hsa04924
3 Aldosterone-regulated sodium reabsorption hsa04960
4 Adrenergic signaling in cardiomyocytes hsa04261
5 Cushing syndrome hsa04934

Pathways related to Conn's Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 AGTR1 CRH GH1 GIPR GNAS NR3C1
2
Show member pathways
12.78 CACNA1H CRH GH1 GNAS KCNJ5 POMC
3
Show member pathways
12.33 CRH GNAS KCNJ5 PRKAR1A
4
Show member pathways
12.26 CYP17A1 GH1 NR3C1 PRL
5
Show member pathways
12.14 AGTR1 CACNA1H CYP11B1 CYP11B2 CYP17A1 CYP21A2
6 11.9 CRH GIPR GNAS POMC
7 11.6 CACNA1H CRH CYP11B1 CYP21A2 GNAS POMC
8 11.58 NR3C1 POMC PRL
9 11.52 CACNA1H GH1 GNAS PRKAR1A
10 11.49 AGTR1 GNAS REN
11
Show member pathways
11.47 CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2
12
Show member pathways
11.38 CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2 POMC
13
Show member pathways
10.97 CYP11B1 CYP11B2 CYP17A1 CYP21A2
14 10.3 CRH POMC

GO Terms for Conn's Syndrome

Cellular components related to Conn's Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 GH1 PRL

Biological processes related to Conn's Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 GH1 NPPA POMC PRL SST
2 response to drug GO:0042493 9.85 CRH GNAS HSD11B2 REN SST
3 regulation of blood pressure GO:0008217 9.8 CYP11B1 NPPA POMC REN
4 steroid biosynthetic process GO:0006694 9.78 CYP11B1 CYP11B2 CYP17A1 CYP21A2
5 steroid metabolic process GO:0008202 9.77 CRH CYP11B1 CYP11B2 CYP17A1 CYP21A2
6 female pregnancy GO:0007565 9.72 CRH GNAS HSD11B2 NPPA PRL
7 renal water homeostasis GO:0003091 9.71 CYP11B2 GNAS PRKAR1A
8 positive regulation of cAMP-mediated signaling GO:0043950 9.69 CRH GIPR GNAS
9 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 GH1 PRL
10 C21-steroid hormone biosynthetic process GO:0006700 9.61 CYP11B1 CYP11B2
11 cellular response to potassium ion GO:0035865 9.61 CACNA1H CYP11B1 CYP11B2
12 response to nutrient GO:0007584 9.6 GIPR SST
13 negative regulation of systemic arterial blood pressure GO:0003085 9.59 CRH NPPA
14 cellular response to hormone stimulus GO:0032870 9.58 CACNA1H CYP11B1 CYP11B2
15 hormone-mediated apoptotic signaling pathway GO:0008628 9.57 CRH SST
16 mineralocorticoid biosynthetic process GO:0006705 9.56 CYP11B2 CYP21A2
17 renin-angiotensin regulation of aldosterone production GO:0002018 9.55 AGTR1 REN
18 regulation of blood volume by renal aldosterone GO:0002017 9.52 CYP11B2 HSD11B2
19 sterol metabolic process GO:0016125 9.43 CYP11B1 CYP11B2 CYP21A2
20 aldosterone biosynthetic process GO:0032342 9.33 CACNA1H CYP11B1 CYP11B2
21 parturition GO:0007567 9.28 CRH
22 cortisol biosynthetic process GO:0034651 9.13 CACNA1H CYP11B1 CYP11B2
23 glucocorticoid biosynthetic process GO:0006704 9.1 CRH CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2

Molecular functions related to Conn's Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.89 CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2
2 heme binding GO:0020037 9.73 CYP11B1 CYP11B2 CYP17A1 CYP21A2
3 iron ion binding GO:0005506 9.71 CYP11B1 CYP11B2 CYP17A1 CYP21A2
4 insulin-like growth factor receptor binding GO:0005159 9.48 GNAS REN
5 corticotropin-releasing hormone receptor 1 binding GO:0051430 9.46 CRH GNAS
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.46 CYP11B1 CYP11B2 CYP17A1 CYP21A2
7 corticosterone 18-monooxygenase activity GO:0047783 9.37 CYP11B1 CYP11B2
8 prolactin receptor binding GO:0005148 9.32 GH1 PRL
9 steroid 11-beta-monooxygenase activity GO:0004507 9.26 CYP11B1 CYP11B2
10 steroid binding GO:0005496 9.26 CYP21A2 HSD11B2 NR3C1 NR3C2
11 hormone activity GO:0005179 9.1 CRH GH1 NPPA POMC PRL SST

Sources for Conn's Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....